World of Psychology

Wyeth Schizophrenia Drug, Bifeprunox, Suffers Setback

By John M. Grohol, PsyD
Founder & Editor-in-Chief

The U.S. Food and Drug Administration (FDA) let Wyeth and its partner, Solvay Pharmaceuticals, know that their newest schizophrenia drug, bifeprunox, needed further research to gain FDA approval. Pharmalot has the story.

While the FDA acknowledged there was enough efficacy data to support short-term use of the drug (e.g., the drug works better than a sugar pill), it didn’t really differentiate itself from other existing schizophrenia drugs on the market.

According to the entry, this likely pushes back approval for the drug to late 2008 or possibly 2009. Assuming, of course, that the new studies continue to show similar positive data for bifeprunox as the existing studies do.

Here’s more information about bifeprunox.


Comments


View Comments / Leave a Comment

This post currently has 3 comments. You can read the comments or leave your own thoughts on our new comments page.


    Last reviewed: By John M. Grohol, Psy.D. on 10 Aug 2007
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2007). Wyeth Schizophrenia Drug, Bifeprunox, Suffers Setback. Psych Central. Retrieved on February 13, 2012, from http://psychcentral.com/blog/archives/2007/08/10/wyeth-schizophrenia-drug-bifeprunox-suffers-setback/

 

From Beliefnet...
Recent Comments
  • Dave Hommel: Dr Grohol, I hope you will be forthright and include this follow-up to our first exchange, as...
  • ablo: Perhaps that’s why Netherlands and Finland have the best education in the world.
  • ablo: Me and my friends were called “evil” for reporting someone who got caught cheating. But moreover,...
  • ablo: I totally agree with anon. “Sad thing is many of them probably ended up in the business world continuing...
  • Dha1967: I agree that the assumption concerning all who Google “depression-type”, etc. are depressed is a...
Subscribe to Our Weekly Newsletter



Find a Therapist


Users Online: 4921
Join Us Now!